Real-world Adoption of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction in Treatment With Entresto in Romania (REACT-HFrEF-RO)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,508
- 试验地点
- 1
- 主要终点
- Percentage of Patients Receiving all Four Guideline-recommended Therapeutic Classes for HFrEF
研究概览
简要总结
The aim of this study was to describe the real-world clinical profile, treatment patterns, and guideline alignment of patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan in routine clinical practice in Romania. The study used secondary use of data, with all analyses conducted on anonymized, pre-existing data collected for routine clinical and administrative purposes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A recorded diagnosis of HFrEF.
- •At least one prescription of sacubitril/valsartan during the identification period.
- •Age ≥18 years at the index date.
排除标准
- •Patients who do not meet inclusion criteria.
研究组 & 干预措施
Sacubitril/Valsartan Cohort
Adults with a recorded diagnosis of HFrEF and ≥1 prescription of sacubitril/valsartan during the study period.
结局指标
主要结局
Percentage of Patients Receiving all Four Guideline-recommended Therapeutic Classes for HFrEF
时间窗: Up to approximately 5 years and 6 months
The four guideline-recommended therapeutic classes include sacubitril/valsartan, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors.
次要结局
- Duration of Sacubitril/Valsartan Treatment(Up to approximately 5 years and 6 months)
- Number of Concomitant Cardiovascular Medications(Up to approximately 5 years and 6 months)
- Percentage of Patients by Demographic Category(Up to approximately 5 years and 6 months)
- Percentage of Patients by Clinical Characteristic Category(Up to approximately 5 years and 6 months)
- Percentage of Patients Who Used Angiotensin-converting Enzyme (ACE) Inhibitors and/or Angiotensin Receptor Blockers Before Starting Sacubitril/Valsartan Treatment(Up to approximately 5 years and 6 months)
- Percentage of Patients by Sacubitril/Valsartan Prescribed Dose at Treatment Initiation(Baseline)
- Percentage of Patients by Dosing Frequency(Up to approximately 5 years and 6 months)
- Percentage of Patients by Use of Individual Guideline-recommended Pharmacological Therapeutic Classes for HFrEF(Up to approximately 5 years and 6 months)
- Percentage of Patients by Most Frequently Prescribed Concomitant Cardiovascular Medications(Up to approximately 5 years and 6 months)